Browse All Grants
99,167 grants found
Showing 61 – 80 of 99,167 grants
An Atlas of Human Brain Cell Variation
PROJECT SUMMARY/ABSTRACT The human brain exhibits profound diversity in biological function and vulnerability to disease. Despite the biomedical and cultural importance of inter-...
Discovering Durable Pan-Coronavirus Immunity
OVERALL SUMMARY Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is a devastating human threat. While successful vaccine programs are underway, genetic drift and immune...
Precision Aging Network: Closing the Gap Between Cognitive Healthspan andHuman Lifespan
SUMMARY/ABSTRACT: Overall Project The strategic vision of the Precision Aging Network (PAN) is to develop the essential scientific knowledge to understand the discrepancy that cu...
Adult Changes in Thought (ACT) Research Program
The Adult Changes in Thought (ACT) U19 Program will expand, modernize, and improve ACT's prospective cohort study to achieve advances in scientific understanding of older adults in...
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site:21-0011
Project Summary The primary goal of current COVID-19 vaccine trials is to measure vaccine efficacy (VE) against clinically significant infection. However, on a population level, va...
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
This Infectious Diseases Clinical Research Consortium Leadership Group (IDCRCLG or LG) is a new, collaborative national partnership of leading infectious diseases, human immunolog...
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
ALS is a lethal neurodegenerative disease accelerated by neuroinflammation. Current FDA-approved therapies have modest benefits and do not address inflammation. To address this, R...
Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS).
ABSTRACT Columbia University, Clene, and Synapticure are partnering and taking an innovative approach to provide persons living with amyotrophic lateral sclerosis ALS (pALS) acro...
Novel Insights into Osteoarthritis, Pain and Function: MOST4
OVERALL ABSTRACT The Multicenter Osteoarthritis (MOST) Study has been a major source of new knowledge about the course of OA and factors that affect it, having published over 180...
Tufts Clinical and Translational Science Institute
TUFTS CTSI OVERALL PROJECT SUMMARY Over its 14 years, Tufts Clinical and Translational Science Institute (CTSI) has brought together partners and collaborators and has grown prog...
Tufts Clinical and Translational Science Institute
TUFTS CTSI OVERALL PROJECT SUMMARY Over its 14 years, Tufts Clinical and Translational Science Institute (CTSI) has brought together partners and collaborators and has grown prog...
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
ALS is a lethal neurodegenerative disease accelerated by neuroinflammation. Current FDA-approved therapies have modest benefits and do not address inflammation. To address this, R...
Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS).
ABSTRACT Columbia University, Clene, and Synapticure are partnering and taking an innovative approach to provide persons living with amyotrophic lateral sclerosis ALS (pALS) acro...
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Scientific Leadership Center
Adolescents and young adults (AYA) under the age of 25 in the United States (US) are the least likely of all age groups to: 1) know their HIV status, 2) initiate PrEP if HIV-negat...
Adult Changes in Thought (ACT) Research Program
The Adult Changes in Thought (ACT) U19 Program will expand, modernize, and improve ACT's prospective cohort study to achieve advances in scientific understanding of older adults i...
Adult Changes in Thought (ACT) Research Program
The Adult Changes in Thought (ACT) U19 Program will expand, modernize, and improve ACT's prospective cohort study to achieve advances in scientific understanding of older adults i...
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
We propose a seamless Phase 2A-2B trial investigating benfotiamine, a prodrug of thiamine, as a first-in- class small molecule treatment for early Alzheimer's disease (AD). We cal...
Harvard Clinical and Translational Science Center
PROJECT SUMMARY/ ABSTRACT Clinical and translational research (CTR) across Harvard is conducted at 17 independent and geographically dispersed institutions, including Harvard Med...
Harvard Clinical and Translational Science Center
PROJECT SUMMARY/ ABSTRACT Clinical and translational research (CTR) across Harvard is conducted at 17 independent and geographically dispersed institutions, including Harvard Med...
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases
Genome editing holds great promise for the treatment of many genetic diseases; however its application in the clinic has been slow due to the lack of the safe delivery tools and s...